Outcomes Associated With the Use of Secondary Prevention Medications After Coronary Artery Bypass Graft Surgery

This publication has 37 references indexed in Scilit:

• Long-Term Adherence to Evidence-Based Secondary Prevention Therapies in Coronary Artery Disease
  Circulation, 2006
• The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial
  American Heart Journal, 2005
• Application of Evidence-Based Medical Therapy Is Associated With Improved Outcomes After Percutaneous Coronary Intervention and Is a Valid Quality Indicator
  JACC, 2005
• Angiotensin-Converting–Enzyme Inhibition in Stable Coronary Artery Disease
  New England Journal of Medicine, 2004
• Secondary prevention after coronary artery bypass graft: a primary issue?
  American Heart Journal, 2004
• Preventing recurrent events long term after coronary artery bypass graft: suboptimal use of medications in a population study
  American Heart Journal, 2004
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
  The Lancet, 2002
• Effects of quinapril on clinical outcome after coronary artery bypass grafting (the QUO VADIS study)
  The American Journal of Cardiology, 2001
• Aspirin use and survival after coronary bypass surgery
  American Heart Journal, 1992
• Timolol-Induced Reduction in Mortality and Reinfarction in Patients Surviving Acute Myocardial Infarction
  New England Journal of Medicine, 1981